Free Trial

iCAD Q1 2023 Earnings Report

iCAD logo
$1.83 +0.06 (+3.39%)
(As of 12/20/2024 05:16 PM ET)

iCAD EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.11
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

iCAD Revenue Results

Actual Revenue
$5.78 million
Expected Revenue
$5.35 million
Beat/Miss
Beat by +$430.00 thousand
YoY Revenue Growth
N/A

iCAD Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Buy this coin BEFORE Inauguration Day … (Ad)

Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.

This could be his favorite coin.

iCAD Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
US Penny Stocks To Watch In December 2024
See More iCAD Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iCAD? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iCAD and other key companies, straight to your email.

About iCAD

iCAD (NASDAQ:ICAD) engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

View iCAD Profile

More Earnings Resources from MarketBeat

Upcoming Earnings